FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249244150> ?p ?o ?g. }

• W2249244150 abstract "9519 Background: The genotype of most GIST in pediatric patients (pts) is “wild type” (WT-GIST), with no detectable KIT or PDGFR-α mutations. Adults with metastatic WT-GIST often have suboptimal results and primary resistance to imatinib (IM) therapy. Treatment with sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor with antiangiogenic and antitumor activities, results in significant clinical benefit, such as improved survival, for adult pts with IM-resistant GIST, including WT-GIST. We report here the treatment of 3 pediatric pts with IM-resistant, metastatic GIST using sunitinib. Methods and Patients: Pt 1 presented at age 17 with numerous abdominal and hepatic GIST metastases. Following surgical debulking and 6 wks of IM treatment, objective progression was noted due to growth of omental masses and a new hepatic lesion. Pt 2 presented at age 8 with an isolated gastric GIST, fully resected, followed by adjuvant IM that continued until resection of a local recurrence 14 mos later. She had 2 more local recurrences and developed lung metastases. Pt 3 presented at age 13 with a large gastric GIST and a retroperitoneal metastasis, both fully resected and followed by adjuvant IM for 18 mos. Six mos after discontinuing IM, recurrent metastatic GIST was noted in the liver and retroperitoneum; IM therapy was resumed with stable disease for 1 yr when new hepatic lesions appeared with progression of the retroperitoneal mass. Pts 1 and 2 had WT-GIST, while genotyping of Pt 3 is pending. Sunitinib, obtained via an expanded-access protocol, was administered in 6-wk cycles, orally QD for 4 wks followed by 2 wks off dosing. Results: All pts have received 5 cycles of sunitinib. All GIST lesions have stabilized or decreased in size by CT imaging, with complete regression of 2 lung nodules in Pt 2. 18FDG-PET imaging obtained in 2 pts showed significant decreases in tumor-associated activity at all disease sites. Side effects with sunitinib have been manageable, including grade 2 GI and hematologic toxicities in pt 1, grade 3 fatigue in pt 2 and grade 3 hematologic toxicity in pt 3. Conclusions: Sunitinib shows important antitumor activity in pediatric pts with IM-resistant GIST. An expanded phase I/II trial of sunitinib in pediatric GIST is warranted. [Table: see text]" @default.
• W2249244150 created "2016-06-24" @default.
• W2249244150 creator A5003791140 @default.
• W2249244150 creator A5020991267 @default.
• W2249244150 creator A5026593581 @default.
• W2249244150 creator A5035376959 @default.
• W2249244150 creator A5041323342 @default.
• W2249244150 creator A5056053037 @default.
• W2249244150 creator A5069791609 @default.
• W2249244150 creator A5086094365 @default.
• W2249244150 creator A5087253387 @default.
• W2249244150 date "2006-06-20" @default.
• W2249244150 modified "2023-09-26" @default.
• W2249244150 title "Sunitinib treatment of pediatric metastatic GIST after failure of imatinib" @default.
• W2249244150 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.9519" @default.
• W2249244150 hasPublicationYear "2006" @default.
• W2249244150 type Work @default.
• W2249244150 sameAs 2249244150 @default.
• W2249244150 citedByCount "11" @default.
• W2249244150 countsByYear W22492441502012 @default.
• W2249244150 countsByYear W22492441502021 @default.
• W2249244150 crossrefType "journal-article" @default.
• W2249244150 hasAuthorship W2249244150A5003791140 @default.
• W2249244150 hasAuthorship W2249244150A5020991267 @default.
• W2249244150 hasAuthorship W2249244150A5026593581 @default.
• W2249244150 hasAuthorship W2249244150A5035376959 @default.
• W2249244150 hasAuthorship W2249244150A5041323342 @default.
• W2249244150 hasAuthorship W2249244150A5056053037 @default.
• W2249244150 hasAuthorship W2249244150A5069791609 @default.
• W2249244150 hasAuthorship W2249244150A5086094365 @default.
• W2249244150 hasAuthorship W2249244150A5087253387 @default.
• W2249244150 hasConcept C121608353 @default.
• W2249244150 hasConcept C126322002 @default.
• W2249244150 hasConcept C143998085 @default.
• W2249244150 hasConcept C16930146 @default.
• W2249244150 hasConcept C2775922572 @default.
• W2249244150 hasConcept C2777583451 @default.
• W2249244150 hasConcept C2778729363 @default.
• W2249244150 hasConcept C2779490328 @default.
• W2249244150 hasConcept C71924100 @default.
• W2249244150 hasConceptScore W2249244150C121608353 @default.
• W2249244150 hasConceptScore W2249244150C126322002 @default.
• W2249244150 hasConceptScore W2249244150C143998085 @default.
• W2249244150 hasConceptScore W2249244150C16930146 @default.
• W2249244150 hasConceptScore W2249244150C2775922572 @default.
• W2249244150 hasConceptScore W2249244150C2777583451 @default.
• W2249244150 hasConceptScore W2249244150C2778729363 @default.
• W2249244150 hasConceptScore W2249244150C2779490328 @default.
• W2249244150 hasConceptScore W2249244150C71924100 @default.
• W2249244150 hasLocation W22492441501 @default.
• W2249244150 hasOpenAccess W2249244150 @default.
• W2249244150 hasPrimaryLocation W22492441501 @default.
• W2249244150 hasRelatedWork W1559702962 @default.
• W2249244150 hasRelatedWork W2006171747 @default.
• W2249244150 hasRelatedWork W2022073747 @default.
• W2249244150 hasRelatedWork W2069672756 @default.
• W2249244150 hasRelatedWork W2081016143 @default.
• W2249244150 hasRelatedWork W2116978122 @default.
• W2249244150 hasRelatedWork W2129878459 @default.
• W2249244150 hasRelatedWork W2521436576 @default.
• W2249244150 hasRelatedWork W264746773 @default.
• W2249244150 hasRelatedWork W3028750840 @default.
• W2249244150 isParatext "false" @default.
• W2249244150 isRetracted "false" @default.
• W2249244150 magId "2249244150" @default.
• W2249244150 workType "article" @default.